COMPANY RESEARCHEntered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Entered chronic-disease macrocyclic peptide research through the Syneron Bio collaboration. No named clinical oral candidate from that collaboration has been disclosed.
Keep the Syneron collaboration; any linaclotide history must reflect the May 2026 assignment to Grand.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| AZ–Syneron oral macrocycle research | Not disclosed · Not disclosed | 未披露 | Quantitative human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Syneron Bio reported nearly $100 million raised across its Series A and A+ rounds, with participation from AstraZeneca and multiple strategic and venture investors. Proceeds support its Synova high-throughput macrocyclic peptide discovery platform and advancement of pipeline programs toward clinical development. The combined financing amount is not a single round, and candidate-level oral clinical data were not disclosed.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
